 Chronic non-specific back pain, CNBP, is a very common condition that can significantly impact a person's quality of life. It is often caused by osteoarthritis, OA, which is characterized by inflammation and degeneration of the facet and sacroiliac joints, as well as the spine itself. OA can lead to biomechanical disturbances, nasoceptive, pain receptors, and neuropathic, sensitivity to touch, changes, and psychological slash emotional changes, all of which combine to create a complex syndrome known as chronic non-specific back pain. Recognizing the importance of OA as a major contributor to CNBP, it is important to treat it with the same strategies used for treating OA of peripheral joints, such as using slow-acting drugs for osteoarthritis, Cicidoa. Alphalotop is one of these drugs, and it has been shown to be effective and safe in treating CNBP. This article was authored by AE Karateev.